Impact of COVID-19 vaccination on symptoms and immune phenotypes in vaccine-naïve individuals with Long COVID.
Impact of COVID-19 vaccination on symptoms and immune phenotypes in vaccine-naïve individuals with Long COVID.
复制标题
COVID-19 疫苗接种对未接种疫苗的长 COVID 个体的症状和免疫表型的影响。
DOI：
10.1101/2024.01.11.24300929
复制
发表时间：
2024
期刊：
影响因子：
--
通讯作者：
Peña-Hernandez,M
中科院分区：
文献类型：
--
作者：
Grady,ConnorB;Bhattacharjee,Bornali;Silva,Julio;Jaycox,Jillian;Lee,LikWee;Monteiro,ValterSilva;Sawano,Mitsuaki;Massey,Daisy;Caraballo,César;Gehlhausen,JeffR;Tabachnikova,Alexandra;Mao,Tianyang;Lucas,Carolina;Peña-Hernandez,M
BackgroundThe symptomatic and immune responses to COVID-19 vaccination of people with Long COVID are poorly characterized.MethodsIn this prospective study，我们评估了16名未接种过疫苗的Long COVID患者接种COVID-19疫苗后症状和免疫应答的变化。在接种疫苗前和接种第一剂疫苗后2、6和12周进行调查。同时，SARS-CoV-2反应性TCR富集，SARS-CoV-2特异性抗体应答，对其他病毒和自身抗原的抗体应答，以及循环细胞因子在接种疫苗前和接种疫苗后6周和12周进行定量。3人健康状况较差，但2人报告接种疫苗后情况短暂改善。一名报告健康状况较差的参与者因胸痛住院两次（每次给药后）。症状结局与血浆生物特征最相关。较高的基线sIL-6 R与症状改善相关，稳定升高的IFN-β和CNTF水平与无改善相关。在接种后6周和12周观察到SARS-CoV-2特异性TCR和刺突蛋白特异性IgG的显著升高。对疱疹病毒和自身antigens.ConclusionsIn这项研究的16人长期COVID，疫苗接种与增加SARS-CoV-2刺突蛋白特异性IgG和T细胞扩增在大多数参与者中的反应性没有变化。特定的免疫特征与接种疫苗后的症状变化相关，大多数参与者在接种疫苗后健康状况改善或没有变化。
BackgroundThe symptomatic and immune responses to COVID-19 vaccination of people with Long COVID are poorly characterized.MethodsIn this prospective study, we evaluated changes in symptoms and immune responses after COVID-19 vaccination in 16 vaccine-naïve individuals with Long COVID. Surveys were administered before vaccination and at 2, 6, and 12 weeks after receiving the first vaccine dose of the primary series. Simultaneously, SARS-CoV-2-reactive TCR enrichment, SARS-CoV-2-specific antibody responses, antibody responses to other viral and self-antigens, and circulating cytokines were quantified before vaccination and at 6 and 12 weeks after vaccination.ResultsAt 12 weeks post-vaccination, self-reported improved health is seen in 10 out of 16 participants, 3 have no change, and 3 have worse health although 2 report transient improvement after vaccination. One participant reporting worse health was hospitalized twice with chest pain (after each dose). Symptom outcomes are most associated with plasma biosignatures. Higher baseline sIL-6R is associated with symptom improvement, and stably elevated levels of IFN-β and CNTF are associated with no improvement. Significant elevation in SARS-CoV-2-specific TCRs and spike protein-specific IgG are observed at 6 and 12 weeks after vaccination. No changes in reactivities are observed against herpes viruses and self-antigens.ConclusionsIn this study of 16 people with Long COVID, vaccination is associated with increased SARS-CoV-2 spike protein-specific IgG and T cell expansion in most participants. Specific immune features are associated with symptom change after vaccination and most participants experience improved health or no change following vaccination.